Shorter treatment course potentially on the horizon for hep C patients
April 15, 2016, Barcelona, Spain: Data from a Phase 2 clinical trial show that an investigational injectable treatment known as RG-101 in combination with a four week course of oral direct-acting antiviral (DAA) treatment was well tolerated and resulted in high virologic response rates post-treatment among Hepatitis C (HCV) infected patients with genotypes 1 and 4, who had not been treated previously. The findings, presented today at The International Liver Congress™ 2016 in Barcelona, Spain are an interim analysis, with ongoing research to assess virologic response over a 48 week follow-up period to further assess the safety and efficacy of a four week treatment course.
The investigational treatment, RG-101 works on microRNA-122, which the virus uses to replicate. Drugs that interfere with miR-122 could inhibit HCV replication, acting earlier in the viral lifecycle than currently approved HCV protease, polymerase or NS5A inhibitors.1 The current standard of care treatment in HCV consists of eight-12 weeks of DAA oral agents.2
"These early results indicate the potential for RG-101 with oral DAA combination therapy to provide an effective Hepatitis C regimen for patients with a short treatment course of just four weeks," said Dr Mihaly Makara from the Buda Hepatology Centre, Budapest, Hungary, and lead study author. "We very much hope the long-term, 48-week follow-up data follows the same trend."
This international study enrolled 79 patients with chronic HCV, genotype 1 or 4 who had not previously received treatment. Each patient received a 2mg/kg injection of RG-101 on Day one, with a four week course of oral DAAs (either ledipasvir/sofosbuvir, simeprevir, or daclatasvir), following by a second 2mg/kg injection of RG-101 on Day 29. The mean baseline viral load among patients was 5.805 IU/mL.
Interim analysis showed that 97.4% (37/38) and 100% (14/14) of patients at eight and 12 weeks respectiviely had a high virologic response. This was determined by assessing HCV levels 'below the lower limit of quantification' (
Source: European Association for the Study of the Liver
Articles on the same topic
- Phase 2 data show treatment efficacy in 'difficult-to-cure' hepatitis C patientsSat, 16 Apr 2016, 21:03:33 UTC
- Potential first-in-class treatment is well-tolerated in patients with chronic hepatitis BSat, 16 Apr 2016, 21:03:23 UTC
- Scientists find a way to cure hepatitis C with 6 weeks of treatmentSat, 16 Apr 2016, 21:03:13 UTC
- New study challenges the concept of treatment failure in hepatitis CSat, 16 Apr 2016, 21:03:04 UTC
- Low-cost generic direct-acting antiviral treatment for hep C is equivalent to branded formulationsSat, 16 Apr 2016, 21:02:54 UTC
- New study demonstrates efficacy of all-oral treatment regimens in adolescents with hepatitis C virusSat, 16 Apr 2016, 21:02:42 UTC
Other sources
- Study: Generic hepatitis C drugs as effective as brand namesfrom UPIMon, 18 Apr 2016, 0:50:37 UTC
- New study challenges the concept of treatment failure in hepatitis Cfrom Science DailySat, 16 Apr 2016, 21:30:46 UTC
- Scientists find a way to cure hepatitis C with 6 weeks of treatmentfrom Science DailySat, 16 Apr 2016, 21:00:55 UTC
- Low-cost generic direct-acting antiviral treatment for hep C is equivalent to branded formulationsfrom Science DailySat, 16 Apr 2016, 21:00:53 UTC
- New study demonstrates efficacy of all-oral treatment regimens in adolescents with hepatitis C virusfrom Science DailySat, 16 Apr 2016, 21:00:52 UTC
- Phase 2 data show treatment efficacy in 'difficult-to-cure' hepatitis C patientsfrom Science DailySat, 16 Apr 2016, 21:00:52 UTC
- Shorter treatment course potentially on the horizon for hep C patientsfrom Science DailySat, 16 Apr 2016, 8:02:35 UTC